cancer

In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda
In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda
Fierce Pharma
GSK
Merck
Keytruda
Jemperli
cancer
Flag link:
Merck KGaA takes back control of PD-L1 cancer drug as Pfizer alliance ends
Merck KGaA takes back control of PD-L1 cancer drug as Pfizer alliance ends
Endpoints
Merck KGaA
Pfizer
cancer
Bavencio
Flag link:
Proposed FDA guidelines to strengthen oversight on accelerated approval cancer drugs
Proposed FDA guidelines to strengthen oversight on accelerated approval cancer drugs
Medical Marketing and Media
FDA
clinical trials
cancer
oncology
accelerated approvals
Flag link:
BioNTech signs deal to co-develop OncoC4's cancer drug
BioNTech signs deal to co-develop OncoC4's cancer drug
Reuters
BioNTech
OncoC4
cancer
oncology
drug development
ONC-392
Flag link:
Keytruda Unlocked: How Should Merck Proceed with Trials?
Keytruda Unlocked: How Should Merck Proceed with Trials?
BioSpace
Keytruda
Merck
cancer
clinical trials
Flag link:
FDA pauses Mersana’s clinical trial after patient dies
FDA pauses Mersana’s clinical trial after patient dies
Endpoints
Mersana
clinical trials
FDA
patient death
cancer
XMT-2056
antibody-drug conjugate
Flag link:
The state of the oncology microbiome therapeutics pipeline at a glance
The state of the oncology microbiome therapeutics pipeline at a glance
Clinical Trials Arena
oncology
cancer
microbiome
drug development
Flag link:
Moderna Eyes Accelerated Approval for mRNA Cancer Vaccine
Moderna Eyes Accelerated Approval for mRNA Cancer Vaccine
BioSpace
Moderna Therapeutics
MRNA
vaccines
cancer
cancer vaccines
Flag link:
Armed with $60M series A and Lilly's backing, Volastra enters clinic via Amgen cancer med
Armed with $60M series A and Lilly's backing, Volastra enters clinic via Amgen cancer med
Fierce Biotech
Volastra Therapeutics
Eli Lilly
funding
sovilnesib
Amgen
cancer
Flag link:
Tempus, Pfizer partner for cancer drug development
Tempus, Pfizer partner for cancer drug development
Pharmaceutical Business Review
Pfizer
Tempus
cancer
drug development
artificial intelligence
machine learning
Flag link:
Keytruda killer: Chipscreen bags Chinese rights to Biocytogen's bispecific antibody
Keytruda killer: Chipscreen bags Chinese rights to Biocytogen's bispecific antibody
Fierce Biotech
cancer
Biocytogen
Chipscreen NewWay Biosciences
Merck
Keytruda
YH008
Flag link:
Roche and Blueprint agree to end collaboration for cancer drug Gavreto
Roche and Blueprint agree to end collaboration for cancer drug Gavreto
Endpoints
Roche
Gavreto
Blueprint Medicines
cancer
Flag link:
BioNTech touts differences with Moderna in race for cancer vaccines
BioNTech touts differences with Moderna in race for cancer vaccines
Endpoints
BioNTech
Moderna Therapeutics
Merck
vaccines
cancer
cancer vaccines
Flag link:
Fresenius Kabi introduces pegfilgrastim biosimilar for cancer patients in US
Fresenius Kabi introduces pegfilgrastim biosimilar for cancer patients in US
Pharmaceutical Business Review
Fresenius Kabi
Stimufend
pegfilgrastim
biosimilars
Neulasta
Amgen
cancer
Flag link:
GSK was warned repeatedly about Zantac impurity but played down risks
GSK was warned repeatedly about Zantac impurity but played down risks
Fierce Pharma
GSK
Zantac
FDA
cancer
Flag link:
In State of the Union, Biden highlights drug prices, cancer, and affordable care
In State of the Union, Biden highlights drug prices, cancer, and affordable care
Chief Healthcare Executive
Joe Biden
drug pricing
healthcare reform
cancer
Flag link:
Oncolytic virus startup TILT raises €22M to advance cancer therapies
Oncolytic virus startup TILT raises €22M to advance cancer therapies
Endpoints
TILT Biotherapeutics
oncolytic viruses
clinical trials
cancer
oncology
Flag link:
Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of-its-Kind Neoantigen Creation Approaches
Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of-its-Kind Neoantigen Creation Approaches
PR Newswire
Grey Wolf Therapeutics
cancer
funding
neoantigens
Flag link:
Bristol Myers doubles down in immuno-oncology patent fight with AZ, this time targeting Imjudo
Bristol Myers doubles down in immuno-oncology patent fight with AZ, this time targeting Imjudo
Fierce Pharma
Bristol Myers Squibb
legal
AstraZeneca
Imjudo
Yervoy
cancer
patents
Flag link:
Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio
Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio
BioSpace
Regen Biopharma
exosomes
cancer
drug development
Flag link:

Pages